



Fred Floberg

Managing Director
(312) 283-0802

Fred.Floberg@thechicagocorp.com

Diane Selph

Managing Director
(312) 283-0828

Diane.Selph@thechicagocorp.com

Nick Nunley

Vice President
(312) 283-0809

Nick.Nunley@thechicagocorp.com

NTCD, LLC

A company founded by Dr. Dale N. Gerding

Has Licensed the Global Rights to Commercialize NTCD-M3, a Phase III-Ready Biopharmaceutical Asset for Prevention of *C. difficile* Infection Recurrence, to



A U.K. clinical stage biotechnology company

Chicago – January 2021. The Chicago Corporation (TCC) announced that it advised NTCD, LLC, a company founded by Dale N. Gerding, MD, MACP, FIDSA, FSHEA, on licensing the global rights to NTCD-M3, a Phase III-ready asset for prevention of *C. difficile* infection (CDI) recurrence. The licensee is Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections.

C. difficile is the leading cause of hospital acquired infection in the U.S. and poor treatments lead to recurrence. In the U.S., there are approximately 500,000 cases of CDI each year; 25% of these initial cases then recur leading to 29,000 deaths per year; CDI places an estimated \$6 billion burden on US healthcare each year. Hospital mortality rates reach up to 25% in frail elderly patients. Current CDI treatment options are limited, with lower efficacy observed when patients are retreated with the same antibiotic for recurrence of CDI.

NTCD-M3, which has completed a Phase II trial, is a potential breakthrough in CDI treatment. Destiny Pharma intends to perform Phase III trials commencing in mid-2022. Clinical data for NTCD-M3 appears superior to current treatments and drugs in development for the treatment of the recurrence of *C. difficile* infection.

TCC worked with NTCD, LLC, and Dr. Dale N. Gerding to identify a licensee for the final phase of development and commercialization of NTCD-M3. Dr. Gerding is an infectious diseases specialist, researcher, professor and hospital epidemiologist, and one of the leading international experts on *C. difficile*. TCC conducted a global marketing process of pharmaceutical companies to complete the transaction. Destiny Pharma was selected as licensee due to its expertise in clinical stage biotechnology, cultural fit with NTCD, LLC, and strategic focus on building a world leading anti-infection Company. TCC provided extensive support and assistance to all parties throughout the due diligence and documentation phases.

About The Chicago Corporation

The Chicago Corporation is a Chicago-based investment banking firm focused on providing middle-market companies with a range of financial and corporate advisory services including merger and acquisitions, institutional debt and equity capital raising. The Firm is committed to a “client-first” approach and its professionals collaborate to find the best market-based solution for the client. For more information about The Chicago Corporation, its Investment Bankers, and Senior Advisors, please visit www.thechicagocorp.com.